Paper42979366PubMed
Biomimetic tumor microenvironment-responsive prodrug amplifies photoimmunotherapy via TLR2 agonist.
Zhi S and 5 others. Acta Pharm Sin B, 2026.
Cite this record
ConductScience Library. Biomimetic tumor microenvironment-responsive prodrug amplifies photoimmunotherapy via TLR2 agonist. Papers, record 42979366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42979366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Biomimetic tumor microenvironment-responsive prodrug amplifies photoimmunotherapy via TLR2 agonist.
- Journal
- Acta Pharm Sin B
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-05
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40123475 | Near-Infrared Light-Responsive Immunomodulator Prodrugs Rejuvenating Immune Microenvironment for "Cold" Tumor Photoimmunotherapy. | Angew Chem Int Ed Engl | 2025 | https://conductscience.org/library/papers/40123475 | PubMed |
| 2 | 35879449 | The complex role of tumor-infiltrating macrophages. | Nat Immunol | 2022 | https://conductscience.org/library/papers/35879449 | PubMed |
| 3 | 35652198 | Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. | Adv Sci (Weinh) | 2022 | https://conductscience.org/library/papers/35652198 | PubMed |
| 4 | 39173439 | Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance. | Drug Resist Updat | 2024 | https://conductscience.org/library/papers/39173439 | PubMed |
| 5 | 38326563 | Dendritic cells as orchestrators of anticancer immunity and immunotherapy. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/38326563 | PubMed |
| 6 | 38551889 | Immunologic tumor microenvironment modulators for turning cold tumors hot. | Cancer Commun (Lond) | 2024 | https://conductscience.org/library/papers/38551889 | PubMed |
| 7 | 37328642 | Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy. | Nat Rev Clin Oncol | 2023 | https://conductscience.org/library/papers/37328642 | PubMed |
| 8 | 37719381 | Discovery of novel aporphine alkaloid derivative as potent TLR2 antagonist reversing macrophage polarization and neutrophil infiltration against acute inflammation. | Acta Pharm Sin B | 2023 | https://conductscience.org/library/papers/37719381 | PubMed |
| 9 | 35217344 | Engineered nanomaterials for synergistic photo-immunotherapy. | Biomaterials | 2022 | https://conductscience.org/library/papers/35217344 | PubMed |
| 10 | 37776767 | Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity. | Biomaterials | 2023 | https://conductscience.org/library/papers/37776767 | PubMed |
| 11 | 33431631 | Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/33431631 | PubMed |
| 12 | 36176917 | Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy. | Acta Pharm Sin B | 2022 | https://conductscience.org/library/papers/36176917 | PubMed |
| 13 | 31406668 | Imaging Dynamic Peroxynitrite Fluxes in Epileptic Brains with a Near-Infrared Fluorescent Probe. | Adv Sci (Weinh) | 2019 | https://conductscience.org/library/papers/31406668 | PubMed |
| 14 | 28288893 | Redox-responsive theranostic nanoplatforms based on inorganic nanomaterials. | J Control Release | 2017 | https://conductscience.org/library/papers/28288893 | PubMed |
| 15 | 32391629 | Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. | EMBO Mol Med | 2020 | https://conductscience.org/library/papers/32391629 | PubMed |
| 16 | 30243297 | Advances in redox-responsive drug delivery systems of tumor microenvironment. | J Nanobiotechnology | 2018 | https://conductscience.org/library/papers/30243297 | PubMed |
| 17 | 36307534 | Targeting drugs to tumours using cell membrane-coated nanoparticles. | Nat Rev Clin Oncol | 2023 | https://conductscience.org/library/papers/36307534 | PubMed |
| 18 | 33426371 | The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. | Bioact Mater | 2021 | https://conductscience.org/library/papers/33426371 | PubMed |
| 19 | 39633050 | Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. | Nature | 2025 | https://conductscience.org/library/papers/39633050 | PubMed |
| 20 | 29582476 | Cell Membrane Coating Nanotechnology. | Adv Mater | 2018 | https://conductscience.org/library/papers/29582476 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42979366
GET https://conductscience.org/api/papers/v1/42979366/references?page=2